ArticleJournal of nanobiotechnology2026
Constructing a biomimetic ECM protective barrier: a strategic interface design for urethral repair to mitigate foreign body reaction.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Urethral reconstruction often fails due to the foreign body reaction (FBR) triggered by the graft, leading to chronic inflammation, fibrosis, and lumen obstruction. To address this challenge, we developed an innovative strategy: a 3D-printed polylactic acid (PLA) scaffold was pre-implanted subcutaneously for 14 days to recruit host-derived fibroblasts, monocytes, and adipose-derived stem cells. These cells secreted a biomimetic extracellular matrix (ECM) rich in collagen, elastin, and glycosaminoglycans (GAGs), resulting in a proteoglycan (PG)-enriched, bioactive tissue-engineered urethral graft (TEUG). This PG-rich matrix interface, characterized by a high density of proteoglycans and glycosaminoglycans that mimic the native urethral microenvironment, closely mimicked native urethral tissue in terms of hydrophilicity, surface topography, roughness, and mechanical compliance. More importantly, compared with commercially available small intestinal submucosa (SIS)-based grafts, it significantly enhanced urothelial cell adhesion, spreading, and oriented spatial organization, effectively recapitulating the functional role of the native PG matrix. In a rabbit anterior urethral replacement model, TEUG not only provided essential structural support and elasticity but also maintained the tubular architecture and physiological distensibility of the urethra to accommodate pressure changes during voiding. Furthermore, it acted as a functional bioactive interface that modulated the local immune microenvironment, attenuated inflammatory responses, and resisted FBR. As a result, tissue homeostasis was preserved and regenerative capacity was promoted, leading to early and orderly re-epithelialization with successful formation of a continuous epithelial layer and contractile smooth muscle tissue. In contrast, SIS-mediated regeneration resulted in aberrant epithelial hyperplasia, ultimately causing luminal narrowing or complete occlusion. Throughout the postoperative observation period, TEUG-reconstructed urethras consistently maintained patent lumens and demonstrated superior voiding function. In summary, by engineering an ECM interface with immunomodulatory and anti-FBR properties, our approach offers a simple, efficient, and clinically translatable strategy to achieve functional regeneration in urethral reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.